Cargando…
A bitter pill to swallow - Polypharmacy and psychotropic treatment in people with advanced dementia
BACKGROUND: Polypharmacy is common in people with dementia. The use of psychotropic drugs (PDs) and other, potentially inappropriate medications is high. The aims of this cross-sectional study were 1) to investigate the use of drugs in people with advanced dementia (PWAD), living at home or in long...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8925050/ https://www.ncbi.nlm.nih.gov/pubmed/35296254 http://dx.doi.org/10.1186/s12877-022-02914-x |
_version_ | 1784669985637924864 |
---|---|
author | Riedl, Lina Kiesel, Esther Hartmann, Julia Fischer, Julia Roßmeier, Carola Haller, Bernhard Kehl, Victoria Priller, Josef Trojan, Monika Diehl-Schmid, Janine |
author_facet | Riedl, Lina Kiesel, Esther Hartmann, Julia Fischer, Julia Roßmeier, Carola Haller, Bernhard Kehl, Victoria Priller, Josef Trojan, Monika Diehl-Schmid, Janine |
author_sort | Riedl, Lina |
collection | PubMed |
description | BACKGROUND: Polypharmacy is common in people with dementia. The use of psychotropic drugs (PDs) and other, potentially inappropriate medications is high. The aims of this cross-sectional study were 1) to investigate the use of drugs in people with advanced dementia (PWAD), living at home or in long term care (LTC); 2) to focus on PD use; and 3) to identify determinants of PD use. METHODS: The study was performed in the context of EPYLOGE (IssuEs in Palliative care for people in advanced and terminal stages of YOD and LOD in Germany). 191 PWAD were included. All drugs that were administered at the date of the examination were recorded. Multiple logistic regression analysis identified determinants of PD use. RESULTS: 96% of PWAD received medication with a median number of four drugs. 49.7% received five or more drugs. According to the Beers Criteria 39% of PWAD ≥ 65 years received at least one potentially inappropriate medication. 79% of PWAD were treated with PDs. Older PWAD and PWAD living in LTC facilities received significantly more drugs than younger PWAD, and PWAD living at home, respectively. Dementia etiology was significantly associated with the use of antipsychotics, antidepressants and sedative substances. Place of living was associated with the use of pain medication. Behavioral disturbances were associated with the use of antipsychotics and sedative substances. CONCLUSIONS: To mitigate the dangers of polypharmacy and medication related harm, critical examination is required, whether a drug is indicated or not. Also, the deprescribing of drugs should be considered on a regular basis. TRIAL REGISTRATION: Clinicaltrial.gov, NCT03364179. Registered 6 December 2017. |
format | Online Article Text |
id | pubmed-8925050 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-89250502022-03-23 A bitter pill to swallow - Polypharmacy and psychotropic treatment in people with advanced dementia Riedl, Lina Kiesel, Esther Hartmann, Julia Fischer, Julia Roßmeier, Carola Haller, Bernhard Kehl, Victoria Priller, Josef Trojan, Monika Diehl-Schmid, Janine BMC Geriatr Research BACKGROUND: Polypharmacy is common in people with dementia. The use of psychotropic drugs (PDs) and other, potentially inappropriate medications is high. The aims of this cross-sectional study were 1) to investigate the use of drugs in people with advanced dementia (PWAD), living at home or in long term care (LTC); 2) to focus on PD use; and 3) to identify determinants of PD use. METHODS: The study was performed in the context of EPYLOGE (IssuEs in Palliative care for people in advanced and terminal stages of YOD and LOD in Germany). 191 PWAD were included. All drugs that were administered at the date of the examination were recorded. Multiple logistic regression analysis identified determinants of PD use. RESULTS: 96% of PWAD received medication with a median number of four drugs. 49.7% received five or more drugs. According to the Beers Criteria 39% of PWAD ≥ 65 years received at least one potentially inappropriate medication. 79% of PWAD were treated with PDs. Older PWAD and PWAD living in LTC facilities received significantly more drugs than younger PWAD, and PWAD living at home, respectively. Dementia etiology was significantly associated with the use of antipsychotics, antidepressants and sedative substances. Place of living was associated with the use of pain medication. Behavioral disturbances were associated with the use of antipsychotics and sedative substances. CONCLUSIONS: To mitigate the dangers of polypharmacy and medication related harm, critical examination is required, whether a drug is indicated or not. Also, the deprescribing of drugs should be considered on a regular basis. TRIAL REGISTRATION: Clinicaltrial.gov, NCT03364179. Registered 6 December 2017. BioMed Central 2022-03-16 /pmc/articles/PMC8925050/ /pubmed/35296254 http://dx.doi.org/10.1186/s12877-022-02914-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Riedl, Lina Kiesel, Esther Hartmann, Julia Fischer, Julia Roßmeier, Carola Haller, Bernhard Kehl, Victoria Priller, Josef Trojan, Monika Diehl-Schmid, Janine A bitter pill to swallow - Polypharmacy and psychotropic treatment in people with advanced dementia |
title | A bitter pill to swallow - Polypharmacy and psychotropic treatment in people with advanced dementia |
title_full | A bitter pill to swallow - Polypharmacy and psychotropic treatment in people with advanced dementia |
title_fullStr | A bitter pill to swallow - Polypharmacy and psychotropic treatment in people with advanced dementia |
title_full_unstemmed | A bitter pill to swallow - Polypharmacy and psychotropic treatment in people with advanced dementia |
title_short | A bitter pill to swallow - Polypharmacy and psychotropic treatment in people with advanced dementia |
title_sort | bitter pill to swallow - polypharmacy and psychotropic treatment in people with advanced dementia |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8925050/ https://www.ncbi.nlm.nih.gov/pubmed/35296254 http://dx.doi.org/10.1186/s12877-022-02914-x |
work_keys_str_mv | AT riedllina abitterpilltoswallowpolypharmacyandpsychotropictreatmentinpeoplewithadvanceddementia AT kieselesther abitterpilltoswallowpolypharmacyandpsychotropictreatmentinpeoplewithadvanceddementia AT hartmannjulia abitterpilltoswallowpolypharmacyandpsychotropictreatmentinpeoplewithadvanceddementia AT fischerjulia abitterpilltoswallowpolypharmacyandpsychotropictreatmentinpeoplewithadvanceddementia AT roßmeiercarola abitterpilltoswallowpolypharmacyandpsychotropictreatmentinpeoplewithadvanceddementia AT hallerbernhard abitterpilltoswallowpolypharmacyandpsychotropictreatmentinpeoplewithadvanceddementia AT kehlvictoria abitterpilltoswallowpolypharmacyandpsychotropictreatmentinpeoplewithadvanceddementia AT prillerjosef abitterpilltoswallowpolypharmacyandpsychotropictreatmentinpeoplewithadvanceddementia AT trojanmonika abitterpilltoswallowpolypharmacyandpsychotropictreatmentinpeoplewithadvanceddementia AT diehlschmidjanine abitterpilltoswallowpolypharmacyandpsychotropictreatmentinpeoplewithadvanceddementia AT riedllina bitterpilltoswallowpolypharmacyandpsychotropictreatmentinpeoplewithadvanceddementia AT kieselesther bitterpilltoswallowpolypharmacyandpsychotropictreatmentinpeoplewithadvanceddementia AT hartmannjulia bitterpilltoswallowpolypharmacyandpsychotropictreatmentinpeoplewithadvanceddementia AT fischerjulia bitterpilltoswallowpolypharmacyandpsychotropictreatmentinpeoplewithadvanceddementia AT roßmeiercarola bitterpilltoswallowpolypharmacyandpsychotropictreatmentinpeoplewithadvanceddementia AT hallerbernhard bitterpilltoswallowpolypharmacyandpsychotropictreatmentinpeoplewithadvanceddementia AT kehlvictoria bitterpilltoswallowpolypharmacyandpsychotropictreatmentinpeoplewithadvanceddementia AT prillerjosef bitterpilltoswallowpolypharmacyandpsychotropictreatmentinpeoplewithadvanceddementia AT trojanmonika bitterpilltoswallowpolypharmacyandpsychotropictreatmentinpeoplewithadvanceddementia AT diehlschmidjanine bitterpilltoswallowpolypharmacyandpsychotropictreatmentinpeoplewithadvanceddementia |